Severity
Moderate
FDA Drug recall · Reported July 14, 2021
Low out of specification results for epinephrine assay.
Fresenius Kabi USA LLC recalled Xylocaine-MPF with Epinephrine 1:200,000, (Lidocaine HCl and Epinephrine Injection, USP),… - a moderate-severity action.
Xylocaine-MPF with Epinephrine 1:200,000, (Lidocaine HCl and Epinephrine Injection, USP),… was recalled by Fresenius Kabi USA LLC in July 14, 2021. Reason: Low out of specification results for epinephrine assay.. Check the official notice for the remedy. Verify recall #D-0651-2021 with the FDA Drug before acting.
The recall
Fresenius Kabi USA LLC issued this moderate-severity FDA Drug recall-Low out of specification results for epinephrine assay..
Sourced from official FDA Drug enforcement records. Verify recall #D-0651-2021 with the agency before acting. Full product description, hazard, remedy, and related recalls are below.
This FDA Drug action (record #D-0651-2021) was formally reported on July 14, 2021, with the manufacturer initiating the action on June 25, 2021. It is classified under Moderate severity (Class II), with a current status of Terminated. Fresenius Kabi USA LLC is listed as the recalling firm, operating out of Melrose Park, IL. Federal records list the affected scope as 234,800 vials.
The documented reason for this recall is: Low out of specification results for epinephrine assay. Distribution data in the federal record shows the product reached: Distributed Nationwide in the USA. Distribution scope directly affects the consumer exposure window and determines whether a recall remains regional or escalates into a nationwide advisory.
Within the same product category the archive holds 6 closely related recalls, 5 from FDA Drug - clustering in a narrow category often points to a systemic quality-control or supplier issue rather than a one-off defect. Always verify the recall number against the official agency record before acting.
Where this recall sits in its category - 14,287 drugs & medications recalls on record
Of 101,704 recalls in the database, 24,878 are high severity, 72,426 moderate, and 4,400 low. This recall is classified moderate severity.
Counts reflect market size and reporting activity, not inherent danger, we do not rank products by risk from raw recall volume.
Severity
Moderate
Affected scope
234,800 vials
Related Recalls
6
5 from same agency
Xylocaine-MPF with Epinephrine 1:200,000, (Lidocaine HCl and Epinephrine Injection, USP), 1%, 300 mg/30 mL, (10 mg/mL), 30 mL Single Dose Vial, 25 Vials per Tray, Rx only, Fresenius Kabi USA, LLC, Lake Zurich, IL 60047. Vial NDC 63323-487-07, Tray NDC 63323-487-37
Low out of specification results for epinephrine assay.
| Attribute | Value |
|---|---|
| Agency | U.S. Food and Drug Administration |
| Severity class | Moderate (Class II) |
| Status | Terminated |
| Recall number | D-0651-2021 |
| Date reported | July 14, 2021 |
| Date initiated | June 25, 2021 |
| Recalling firm | Fresenius Kabi USA LLC |
| Firm location | Melrose Park, IL |
| Affected scope | 234,800 vials |
| Distribution | Distributed Nationwide in the USA |
Profile values are sourced directly from the official FDA Drug enforcement record. Source: U.S. Food and Drug Administration.
What to do with this recall
Match your product against the recall record, then act on the agency remedy.
This page summarizes the official FDA Drug record for research and awareness; it is not legal, medical, or safety advice. Verify with the issuing agency before acting.
Other recalls in the same product category, useful for spotting patterns across the same defect class or manufacturer.
AbbVie Inc. · 2026-06-03
Llorens Pharmaceuticals International Division, Inc. · 2026-05-27
Safecor Health, LLC · 2026-05-27
IntegraDose Compounding Services LLC · 2026-05-27
Lupin Pharmaceuticals Inc. · 2026-05-27
Compare this recall with PRED MILD, prednisolone acetate ophthalmic suspension, USP,… →
Every figure on PlainRecalls is rendered directly from official FDA, CPSC and NHTSA recall records, no number is typed in by an editor. This recall: FDA Drug, reported July 14, 2021. Severity classes follow each agency's own taxonomy (FDA Class I/II/III; CPSC and NHTSA by hazard type), and related-recall context is computed across the full archive. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of July 2026.